MapLight Therapeutics welcomes Maria Walker to its Board of Directors

– USA, CA –  MapLight Therapeutics, a clinical-stage biopharmaceutical company, today announced the appointment of Maria Walker to its Board of Directors, bringing more than 30 years of experience working with public and private companies across a variety of sectors, including healthcare, technology, venture capital, and private equity.

“We are thrilled to welcome Maria to MapLight’s board. Maria’s deep financial background and wealth of experience as a strategic advisor to growing biotech companies make her a pivotal addition to our board as we grow the organization and move our second pipeline asset, ML-007/PAC, into Phase 2 clinical trials later this year,” said CEO and Co-Founder, Dr. Chris Kroeger.

Maria Walker will join the audit committee.

About Maria Walker

Ms. Walker’s extensive experience includes her most recent role as Founding Partner and CFO at Patient Square Capital, an investment firm dedicated to healthcare. Prior to that, Ms. Walker held various roles of increasing responsibility at KPMG across nearly two decades, including as a global lead partner of private equity, partner in charge of KPMG’s Bay Area Asset Management practice, and as Senior Director of the Venture Capital Practice. In addition to her experience with KPMG, she held several senior roles in the venture capital industry, including Administrative Partner, COO and CFO of Forward Ventures, and CFO of Lightspeed Venture Partners.

Ms. Walker also served as Audit Committee Chairman of ForgeRock and as CFO of Montes Archimedes Acquisition Corp.

“This is an exciting time for MapLight and neuropsychiatry,” said Maria Walker. “I am honored to join the board. MapLight’s neuroscience expertise, pipeline, and the rapidity with which it has progressed assets from discovery to clinical development is impressive. I am inspired by the leadership team’s passion and dedication to MapLight’s mission to improve the lives of patients and families living with some of the most difficult to treat CNS conditions. I look forward to contributing to those efforts as a member of the board.”

Ms. Walker holds a degree in Economics from the University of California, San Diego.

About MapLight Therapeutics

MapLight is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. MapLight was founded by globally-recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. MapLight’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.